IVVD
Company Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 53.43M | 25.38M | 0 | 0 | 0 | 0 |
| Net Income | (52.49M) | (169.93M) | (198.64M) | (241.32M) | (226.79M) | (111.98M) |
| EPS | -0.30 | -1.43 | -1.81 | -2.17 | -2.11 | -0.59 |
| Free Cash Flow | (58.29M) | (170.63M) | (173.78M) | (221.69M) | (184.82M) | (14.57M) |
| FCF / Share | -0.34 | -1.44 | -1.59 | -2.05 | -1.67 | -0.13 |
| Operating CF | (58.13M) | (170.49M) | (173.16M) | (219.99M) | (184.74M) | (14.57M) |
| Total Assets | 276.88M | 129.51M | 229.18M | 383.17M | 620.09M | 117.38M |
| Total Debt | 2.49M | 1.30M | 2.17M | 3.72M | 0 | 0 |
| Cash & Equiv | 226.69M | 69.35M | 200.64M | 92.08M | 542.22M | 114.99M |
| Book Value | 241.54M | 67.54M | 177.47M | 355.97M | 558.02M | (65.25M) |
| Return on Equity | -0.22 | -2.52 | -1.12 | -0.68 | -0.41 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.74M | 17.21M | 13.13M | 11.79M | 11.30M | 13.82M | 9.30M | 2.26M | 0 | 0 | 0 | 0 |
| Net Income | (41.40M) | (11.07M) | (10.47M) | (14.66M) | (16.29M) | (18.44M) | (60.74M) | (47.25M) | (43.50M) | (73.65M) | (39.44M) | (50.23M) |
| EPS | -0.13 | -0.06 | -0.06 | -0.12 | -0.14 | -0.15 | -0.51 | -0.40 | -0.38 | -0.67 | -0.36 | -0.46 |
| Free Cash Flow | (42.44M) | (15.46M) | (8.25M) | (13.31M) | (21.27M) | (37.60M) | (41.07M) | (41.60M) | (50.35M) | (59.24M) | (35.35M) | (37.38M) |
| FCF / Share | -0.14 | -0.09 | -0.05 | -0.11 | -0.18 | -0.32 | -0.34 | -0.35 | -0.44 | -0.54 | -0.32 | -0.34 |
| Operating CF | (41.71M) | (15.46M) | (8.25M) | (13.30M) | (21.13M) | (37.61M) | (41.07M) | (41.60M) | (50.21M) | (59.24M) | (35.35M) | (37.39M) |
| Total Assets | 241.74M | 276.88M | 139.16M | 89.14M | 103.74M | 129.51M | 161.92M | 177.35M | 215.47M | 229.18M | 274.92M | 315.41M |
| Total Debt | 8.63M | 2.49M | 2.68M | 2.96M | 894,000 | 1.30M | 1.63M | 681,000 | 1.76M | 2.17M | 2.56M | 2.96M |
| Cash & Equiv | 184.15M | 226.69M | 84.97M | 34.91M | 48.08M | 69.35M | 106.87M | 147.88M | 189.39M | 200.64M | 181.82M | 121.95M |
| Book Value | 203.05M | 241.54M | 93.07M | 42.79M | 54.15M | 67.54M | 83.16M | 140.64M | 178.50M | 177.47M | 246.50M | 281.56M |
| Return on Equity | -0.20 | -0.05 | -0.11 | -0.34 | -0.30 | -0.27 | -0.73 | -0.34 | -0.24 | -0.42 | -0.16 | -0.18 |
